60-OR: High Prevalence of Multiorgan Steatosis and Fibroinflammation, Identified by Multiparametric Magnetic Resonance Imaging, in People with Type 2 Diabetes

Abstract

Type 2 diabetes (T2D) is a multi-system disease characterised by a high prevalence of co-morbidities and micro- and macro-vascular complications. The aim of this study was to provide --comprehensive assessment of multi-organ health and pre-clinical detection of diabetes-related organ damage with a single, non-contrast MRI scan. We recruited 138 adults with T2D (median 62 yrs, 60 % male; BMI 31 kg/m2, 92 % on metformin [NCT04114682]) . MRI data were acquired to derive organ-specific measures of size, fat deposition, fibroinflammation, body composition and aortic distensibility (CoverScan®, Perspectum Ltd.) . Reference values of MRI metrics were based on 92 healthy volunteers and published literature. Statistical significance of co-prevalence was assessed by simulation assuming that values were independently binomially distributed. There was a high prevalence of abnormality in individual organs (Figure, left) . Prevalence of low skeletal muscle index and elevated pancreatic fat were associated with T2D duration. There was further evidence of co-prevalence of organ abnormalities (Figure right; 86 % with at least 2 organs affected) . Aortic stiffness was frequently associated with organ steatosis. MRI assessment can enrich the current blunt assessment of multi-organ abnormalities in T2D to inform earlier intervention and treatments. Disclosure N.Eichert: Employee; Perspectum Ltd. S.Ali: Other Relationship; NICE committee for diabetes. G.Thanabalasingham: Speaker's Bureau; Boehringer Ingelheim International GmbH. D.Cuthbertson: Other Relationship; AstraZeneca, Novo Nordisk. K.Gibbons: None. A.Hamid: None. R.Ramkhelawon: Other Relationship; NICE committee. V.E.Woolgar: None. R.Suriano: None. H.B.Thomaides-brears: Employee; Perspectum Ltd, Stock/Shareholder; Perspectum Ltd. R.Banerjee: Employee; Perspectum Ltd., Other Relationship; Perspectum Ltd., Stock/Shareholder; Perspectum Ltd. G.Kemp: None. Funding Innovate UK (Digital Health Technology Catalyst scheme) ; Perspectum Ltd.